Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | GLUL | P15104 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | ARG2 | P78540 | 3/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747426 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| SCHEMBL21747440 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| SCHEMBL21747424 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| SCHEMBL1192036 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| Ap-7 SCHEMBL12648647 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| Ap-7 SCHEMBL154303 | 1.00 | BHMT (0.67) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747427 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747430 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747425 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL | |
| Water SCHEMBL21747439 | 0.98 | BHMT (0.65) | BHMTPOLBKMT2ATDP1GLUL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | claimed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | claimed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | claimed |
| US-20250161238-A1 | NMDAR Antagonists Prevent Ageing and Aging-Associated Conditions and Diseases Through Increasing 20S Proteasome Activity | SAHIN FIKRET (TR) | 2025-05-22 | — | — | US | disclosed |
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | disclosed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | disclosed |
| US-12121526-B2 | Targeting NCCA-ATP channel for organ protection following ischemic episode | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2024-10-22 | — | — | US | disclosed |
| EP-3056200-B1 | HUPERZINE FOR USE IN TREATING SEIZURE | HARVARD COLLEGE (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | disclosed |
| US-20220193096-A1 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-23 | — | — | US | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2259068-B1 | Capture compounds and methods for analyzing the proteome | CAPROTEC BIOANALYTICS GMBH (DE) | 2013-08-14 | — | — | EP | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| EP-2053406-A2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | caprotec bioanalytics GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| EP-0432994-A2 | Excitatory amino acid antagonists as anti-emetic drugs | Olney, John William (US) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PTMS, QPCTL, SRMS | BHMT 3844/4885POLB 3569/4885KMT2A 2736/4885 |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | BHMT 440/4885POLB 4282/4885KMT2A 3285/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | BHMT 3847/4885POLB 1460/4885KMT2A 4400/4885 |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CHLSN, PTMS, SRMS | BHMT 2941/4885POLB 3051/4885KMT2A 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.